Compare Alibaba Group (BABA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs Viatris Inc — how do they compare? Alibaba Group trades at $125.1 (market cap $309.65B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Alibaba Group is far larger — about 16.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| BABA | VTRS | |
|---|---|---|
Market Cap | $309.65B | $18.69B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $17.86 |
52-Week Low | $94.83 | $9.49 |
Enterprise Value | $304.43B | $30.81B |
Dividend Yield | 0.79% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Viatris (VTRS) trades at $16.43, up 0.86% with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, with revenues rising 5% year-over-year. However, fundamental challenges persist with negative net income margin (-2.79%) and elevated P/E ratio (236.2). Recent developments include FDA approval for Gwyn Lo contraceptive patch and strategic divestitures to sharpen focus.
While Viatris shows operational improvements with consistent cash flow generation, the stock faces headwinds from profitability challenges and high valuation multiples. The mixed analyst sentiment (30.77% buy rating) reflects uncertainty about the company's turnaround trajectory. Key risks include ongoing margin pressure and competitive threats in the generic pharmaceutical space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
